NCT03093168View on ClinicalTrials.gov

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 15, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

February 29, 2020

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Anti-BCMA CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-BCMA CAR

DRUG

Fludarabine

dose: 25mg/m2/d

DRUG

Cyclophosphamide

Dose: 40mg/kg

Trial Locations (1)

Unknown

RECRUITING

Henan Province of TCM, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

Hrain Biotechnology Co., Ltd.

INDUSTRY

collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

collaborator

Shanghai Changzheng Hospital

OTHER

lead

The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

OTHER